India based Fertility treatments chain Indira IVF announced a foray into the diagnostics sector with a Rs 60 crore investment over next five years
Fertility treatments chain Indira IVF on Tuesday announced its entry into the diagnostics sector with a Rs 60 crore investment over the next five years. The TA Associates-backed chain plans to invest Rs 60 crore for Indira Pathlabs over next five years which may even exceed depending on future plans and opportunities, the statement said
The city-based company, which claims to India’s largest fertility treatments chain, plans to offer pathology tests catering to the needs of women and children, as per an official statement.
The organisation has inaugurated its state-of-the-art laboratories in Lucknow, New Delhi, Patna and Mumbai, and aims to launch a total of 30+ pathology laboratories in strategic geographies by FY24 and two super speciality labs in Mumbai and Delhi.
Indira PathLabs will leverage Indira IVF’s already established network of 114 centres in the country. In the Phase 1 of expansion in FY23, it will gradually expand services to all major geographies where it has a robust presence including Lucknow, Patna, New Delhi, Mumbai, Pune, Udaipur, Jaipur, Varanasi, Kolkata, Ranchi, Bhubaneswar, and Bengaluru to name a few.
Dr Nitiz Murdia – Managing Director & Co-Founder of Indira IVF said, “Genetic testing is an essential tool to ascertain the future child’s health and check for the presence of any genetic anomalies. In this regard, in addition to our pathology services, we also seek to introduce two genetic testing laboratories in the country that can perform highly specialised tests required for the prediction of such genetic anomalies in the child conceived.”
News Desk – Infertilityhospitals.com, December 21, 2022